Beta-containing COVID-19 booster vaccine found to cross-neutralize
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates
Moderna COVID-19 vaccine - Wikipedia
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Vaccines, Free Full-Text
Jean-François Toussaint on LinkedIn: #covid19
Neutralization of SARS-CoV-2 variants by NVX-CoV2373 vaccinee plasma.
mutI-tri-RBD induced significantly higher titer of neutralizing
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Dean Huang's Instagram, Twitter & Facebook on IDCrawl
Dean Huang's Instagram, Twitter & Facebook on IDCrawl
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants
Frontiers The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study
Latest on Omicron Variant and COVID-19 Vaccine Protection – NIH Director's Blog
Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates
